The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance th…

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

~Estimated

~$10 – $7,500

TakedaNCT06747351

Phase 2

A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective cover…

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

~Estimated

~$10 – $7,500

TakedaNCT06798012

A Global Real-World Study to Assess HyQvia Use and Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Switching to HyQvia

The main aims of this study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why t…

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

~Estimated

~$10 – $1,125

TakedaNCT06538064